Reversible sideroblastic anemia associated with the tetracycline analogue COL-3

Authors


  • This article is a U.S. Government work and, as such, is in the public domain in the United States of America.

Abstract

Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases. Am. J. Hematol. 67:51–53, 2001. Published 2001 Wiley-Liss, Inc.

Ancillary